NICE backs Pfizer's Bosulif in first reappraisal of cancer fund drug

The U.K.'s NICE issued a final appraisal determination recommending use of leukemia drug Bosulif bosutinib from Pfizer Inc. (NYSE:PFE). The recommendation

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE